Main Content

Search loading...

Treating Brain Metastases with Leksell Gamma Knife®

Brain metastases is the largest single indication for Gamma Knife® surgery , because of the successful outcome and the method’s easiness and patient friendliness.

Gamma Knife surgery shows good tumor rate control and improves quality of life1.

More than 200 papers discuss the advantages of stereotactic surgery with Leksell Gamma Knife. Studies also point in the direction that SRS has a better clinical outcome compared to whole brain radiation therapy (WBRT) alone (RTOG9508).

AANS/CNS new treatment guidelines for the management of brain metastases (December 2009);
MD Anderson Phase III study concludes that patients receiving SRS plus WBRT are at greater risk of significant decline in learning and memory function compared to if they receive SRS only (November 2009);

Paper on “Stereotactic Radiosurgery for the Management of Brain Metastases” by John H. Suh (Cleveland Clinic) published in The New England Journal of Medicine (March 2010):
Nature Reviews Clinical Oncology publishing article discussing the MD Anderson study (targeting medical oncologists)

Leksell Gamma Knife is designed for fast and efficient treatment of multiple brain metastases. No other technology has the ability to treat multiple targets in the brain with the same clinical outcome and speed as Leksell Gamma Knife Perfexion . Today more than 200,000 patients have been treated with Gamma Knife surgery for brain metastases.

Managing brain metastases means prolonged life and improved quality of life and should always be considered in the choice of treatment method.


According to the American Cancer Society, between 20 and 40 percent of all cancer patients develop metastatic tumors in the brain.

This is the single most common type of intracranial tumor. In the US alone, around 150,000 people are diagnosed with brain metastases each year. The incidence continues to increase as advances are made in the treatment of systemic cancer.

Improvements in imaging quality and accessibility have also contributed to the increased number of patients in whom metastasis is diagnosed. Modern imaging technology can detect smaller lesions, allowing for earlier intervention than was possible in the past and perhaps increasing the opportunity to control brain disorder. The majority of patients who have a local brain tumor control die of extracranial disease progression, whereas those with uncontrolled brain metastases more often die of neurological causes. Therefore, achieving local control is of primary importance when considering treatment options in patients with brain metastases3.


  1. Michael L. Smith Neurosurg. Focus / Volume 22 / March, 2007
  2. Moksha Ranasinghe Neurosurg. Focus / Volume 22 / March, 2007

Your Feedback:

Send message Close window